Aventis Behring Makes Significant Investments to Expand Manufacturing Capabilities

Aventis Behring plans to invest more than $65 million to enhance manufacturing technology and product availability

05-Aug-2002

King of Prussia, PA, - Aventis Behring L.L.C. announced today the approval of a $14.5 million USD investment to upgrade its basic fractionation facilities in Marburg, Germany and begin design plans for a new basic fractionation facility. This investment will fund the first two phases of the company's three-phase plan to upgrade its manufacturing technology and enhance product availability worldwide. The goal of the first phase is to upgrade the existing fractionation facility in Marburg, home to the company's largest manufacturing facility in Europe, to bridge the time until a new basic fractionation facility becomes operational. The completion of the first phase is intended to accelerate the earlier registration of new immunoglobulin products into new markets. The first phase will begin with a facility shutdown that will continue for approximately five months, while the improvements are made. In advance of the shutdown, Aventis Behring will have produced a surplus supply of therapies for patients to ensure steady, continuous product availability. The goal of phase two is to finish the engineering design plans for the construction of a new basic fractionation facility. Successful completion of the design work will form the foundation for the approval and funding of phase three, the construction, start-up and validation of a new basic fractionation facility in Marburg, which will require an investment in excess of $50 million USD. "This three-phased plan is exciting as it represents one of the largest single investments we have made in our manufacturing facilities to date," says Gail Schulze, Chief Operating Officer, Aventis Behring. "More importantly, this investment will positively impact the patient communities that depend on our life-saving therapies. This plan supports our commitment to provide patients and their families worldwide with upgraded and new manufacturing facilities that can further enhance product availability as well as standards in product quality."

https://www.chemeurope.com/en/news/12748/aventis-behring-makes-significant-investments-to-expand-manufacturing-capabilities.html